Coronary heart disease (CHD) in lupus: round up the usual suspects?

Urowitz MB , Bookman AAM , Koehler BE , Gordon DA , Smythe HA , Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus . Am J Med 1976; 60: 221-225 .

Abu-Shakra M , Urowitz MB , Gladman DD et al. Mortality studies in systemic lupus erythematosus. Results from a single centre. I. Causes of death . J Rheumatol 1995; 22: 1259-1264 .

Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus . Arthritis Rheum 1999; 42: 338-346 .

Manzi S , Meilahn EN , Rairie JE et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham study . Am J Epidemiol 1997; 145: 408-415 .

Roman MJ , Shanker BA , Davis A et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus . N Engl J Med 2003; 349: 2399-2406 .

Asanuma Y , Oeser A , Shintani AK et al. Premature coronary artery atherosclerosis in systemic lupus erythematosus . N Engl J Med 2003; 349: 2407-2415 .

Bruce IN , Burns RJ , Gladman DD , Urowitz MB. Single photon emission computed tomography dual isotope myocardial perfusion imaging in women with systemic lupus erythematosus. I. Prevalence and distribution of abnormalities . J Rheumatol 2000; 27: 2372-2377 .

Manzi S , Selzer F , Sutton-Tyrrell K et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus . Arthritis Rheum 1999; 42: 51-60 .

Bruce IN , Urowitz MB , Gladman DD , Ibanez D , Steiner G. Risk factors for coronary heart disease in women with systemic lupus erythematosus. The Toronto Risk Factor Study . Arthritis Rheum 2003; 48: 3159-3167 .

Bulkley BH , Roberts WC. The heart in systemic lupus erythematosus and the changes induced by corticosteroid therapy. A study of 36 necropsy patients . Am J Med 1975; 58: 243-263 .

Doria A , Schoenfeld Y , Wu R et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus . Ann Rheum Dis 2003; 62: 1071-1077 .

MacGregor AJ , Dhillon VB , Binder A et al. Fasting lipids and anticardiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosus . Ann Rheum Dis 1992; 51: 152-155 .

Bruce IN , Gladman DD , Urowitz MB. Premature atherosclerosis in SLE . Rheum Dis Clin North Am 2000; 26: 257-278 .

Bruce IN , Urowitz MB , Gladman DD , Hallett DC. Natural history of hypercholesterolaemia in systemic lupus erythematosus . J Rheumatol 1999; 26: 2137-2143 .

Esdaile JM , Abrahamowicz M , Grodzicky T et al. Traditional risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus . Arthritis Rheum 2001; 44: 2331-2337 .

Costenbader KH , Liang MH. Practical and theoretical barriers to the prevention of accelerated atherosclerosis in systemic lupus erythematosus . Arthritis Res Ther 2003; 5: 178-179 .

Lima DS , Sato EI , Lima VC , et al. Brachial endothelial function is impaired in patients with systemic lupus erythematosus . J Rheumatol 2001; 29: 292-297 .

Selzer F , Sutton-Tyrrell K , Fitzgerald SG et al. Comparison of risk factors for vascular disease in carotid artery and aorta in women with systemic lupus erythematosus . Arthritis Rheum 2004; 50: 151-159 .

Posados-Romero C , Torres-Tamayo M , Zamora-Gonzalez J et al. High insulin levels and increased low-density lipoprotein oxidizability in pediatric patients with systemic lupus erythematosus . Arthritis Rheum 2004; 50: 160-165 .

Petri M , Roubenoff R , Dallal GE , Nadeau MR , Selhub J , Rosenberg IH. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus . Lancet 1996; 348: 1120-1124 .

Wajed J , Ahmad Y , Durrington PN , Bruce IN. Prevention of cardiovascular disease in systemic lupus erythematosus-proposed guidelines for risk factor management . Rheumatology 2004; 43: 7-12 .

Wick G , Schett G , Amberger A et al. Is atherosclerosis an immunologically mediated disease ? Immunol Today 1995; 16: 27-33 .

Gladman DD , Urowitz MB. Morbidity in systemic lupus erythematosus . J Rheumatol 1987; 14(suppl 13): 223-226 .

Pineau CA , Gladman DD , Ibanez D , Urowitz MB. Lupus disease activity and coronary artery disease . Arthritis Rheum 2001; 44(suppl): S287-S287 .

Wahl DG , Guillemin F , de Maistre E et al. Risk of venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus . Lupus 1997; 6: 467-473 .

Vaarala O , Manttari M , Manninen V et al. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men . Circulation 1995; 91: 23-27 .

Hasunuma Y , Matsuura E , Makita Z , Katahira T , Nishi S , Koike T. Involvement of beta 2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages . Clin Exp Immunol 1997; 107: 569-573 .

Vaarala O. Auoantibodies to modified LDLs and other phospholipid-protein complexes as markers of cardiovascular risk . J Intern Med 2000; 247: 381-384 .

Pierangeli SS , Colden-Stanfield M , Liu X , Barker JH , Anderson GL , Harris EN. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo . Circulation 1999; 99: 1997-2002 .

Kannel WB. Metabolic risk factors for coronary artery disease in women: perspective from the Framingham Study . Am Heart J 1987; 114: 413-419 .

Gilboe IM , Kvien TK , Husby G. Disease course in systemic lupus erythematosus: changes in health status, disease activity, and organ damage after 2 years . J Rheumatol 2001; 28: 266-274 .